



# PETVIVO HOLDINGS, INC. ENGAGES CYNTHIA JENKINS AS CHIEF FINANCIAL OFFICER

MINNEAPOLIS, MINNESOTA, USA, August 29, 2017 /EINPresswire.com/ -- Press Release New Hire Cynthia Jenkins

(All Press Releases Will Be Available for Viewing on Facebook or the Web at [www.petvivo.com](http://www.petvivo.com) )

Created:

TuesdaWednesday, 8-30-2017

FOR IMMEDIATE RELEASE

## PETVIVO HOLDINGS, INC. ENGAGES CYNTHIA JENKINS AS CHIEF FINANCIAL OFFICER

PetVivo Holdings, Inc. OTCMARKETS: PETV ([www.petvivo.com](http://www.petvivo.com)) is pleased to announce that Cynthia Jenkins will join the PetVivo team as the Company's Chief Financial Officer (CFO). For more than forty years Ms. Jenkins has specialized in facilitating startup companies to build solid foundations in their financial and compliance/regulations departments. She has extensive expertise in finance, accounting and treasury functions in addition to regulatory compliance and audit expertise.

"I am excited to have Cindy Jenkins join our team. Cindy has the experience that is difficult to find," noted Wes Hayne, the Company's CEO, "Her work ethic to hit deadlines is unparalleled and necessary in a growth company with a constant change in dynamics."

Over her career, Ms. Jenkins has held the offices of CEO, President, Vice President, CFO, and Secretary/Treasurer and has been in upper management of small to mid-size broker-dealers and early stage companies. She has extensive financial, compliance, and operational experience to facilitate new and existing firms grow and acclimate to the rules and regulations of the SEC and FINRA. She also specializes in AML audits, 3012 GAP Analysis testing, and documenting companies' Written Supervisory and Compliance Procedures. She holds Series 7, 24, 27, 52, 63, and 99 securities licenses.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company's product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company's products, production processes and biomaterials. PetVivo's lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary

human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne

CEO

PetVivo Holdings, Inc.

Email: [info@petvivo.com](mailto:info@petvivo.com)

Main: (612) 296-7305

Direct: (763) 443-7272

John Lai

Petvivo Holdings, Inc.

612-296-7305

[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.